TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
Objective. To evaluate the effectiveness and safety of TAS-102 monotherapy and combination therapy with bevacizumab in the treatment of metastatic colorectal cancer. Methods. The PubMed, Web of Science, MEDLINE, and Cochrane Library databases were searched for the literature on TAS-102 treatment of...
Saved in:
Main Authors: | Cheng-Jiang Liu, Ting Hu, Ping Shao, Wu-Yang Chu, Yu Cao, Feng Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2021/4014601 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
by: Ritam Joarder, et al. -
Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer
by: Ruohong Lin, et al.
Published: (2024-12-01) -
Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01) -
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
by: Toshiaki Takahashi, et al.
Published: (2025-01-01) -
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer
by: Julien Taieb, et al.
Published: (2025-01-01)